Bausch Health Companies Inc. (BHC) stock
Close on Nov 12, 2026Market cap $3.09BP/E –Yield –
Bausch Health Companies Inc. grew revenue 10.8% to $11.11B over the twelve months to Sep 30, 2026. Operating income fell 34.3% to $1.25B, moving the operating margin from 18.9% to 11.2%. Free cash flow was $1.87B, up 70.3% from a year earlier. At the latest close the market valued the company at $3.09B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.09B
- P/E ratio
- –
- Price to sales
- 0.28
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 60.40%
Fundamentals
- Revenue
- $11.11B
- Net income
- -$841.00M
- EPS, diluted
- -$2.29
- Free cash flow
- $1.87B
- Book value per share
- -$3.49
- Diluted shares
- 381M
Trading
- Next earnings
- Feb 17, 2027 (estimated, after the close)
- Previous close
- $8.35
- Open
- $8.36
- Day's range
- $8.24 – $8.43
- Volume
- 2,350,370
- Average volume (20 days)
- 4,769,317
- Beta (5 years)
- 1.00
- 52-week range
- $4.33 – $9.04
- RSI (14 days)
- 67.0
- Volatility (1 year)
- 62.8%
- Relative volume
- 0.69×
- WACC
- 6.6%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BHC | S&P 500 | Difference | BHC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +39.1% | -2.7% | +41.8 pts | ||
| 3 months | +32.9% | -1.7% | +34.6 pts | ||
| Year to date | +18.7% | +11.9% | +6.8 pts | ||
| 1 year | +18.9% | +12.0% | +6.9 pts | ||
| 3 years | +21.1% | +78.2% | −57.0 pts | +6.6% | +21.2% |
| 5 years | -68.8% | +73.2% | −142.0 pts | -20.8% | +11.6% |
| 10 years | -54.2% | +309.6% | −363.8 pts | -7.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bausch Health Companies filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Bausch Health Companies
Pharmaceutical Preparations
Bausch Health Companies Inc. develops, manufactures, and markets specialty pharmaceuticals, over-the-counter products, and medical devices. The company focuses primarily on therapeutic areas such as gastroenterology, hepatology, neurology, dermatology, and eye health. Its business operates across five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Salix handles U.S. gastrointestinal treatments, while Solta Medical provides aesthetic medical systems. The International segment manages pharmaceutical and consumer healthcare sales outside the United States. Diversified covers U.S. neurology, dermatology, dentistry, and generic medications, and Bausch + Lomb delivers vision care, surgical platforms, and ophthalmic pharmaceuticals to patients and healthcare providers.
Company profile, executives and historyBausch Health Companies stock: common questions
What is Bausch Health Companies's stock price?
BHC closed at $8.25 on Nov 12, 2026, down 1.20% on the day. Over the past 52 weeks it traded between $4.33 and $9.04.
What is Bausch Health Companies's market cap?
Bausch Health Companies was worth $3.09B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BHC's P/E ratio?
Bausch Health Companies lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.29), so it has no meaningful P/E ratio.
How much revenue does Bausch Health Companies make?
Bausch Health Companies reported revenue of $11.11B for the twelve months to Sep 30, 2026, up 10.8% from a year earlier.
Does Bausch Health Companies pay a dividend?
No. Bausch Health Companies has not paid a cash dividend over the last twelve months.
When does Bausch Health Companies report earnings next?
Bausch Health Companies is expected to report Q4 FY2026 results on Feb 17, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BHC stock performed over the past year?
Including dividends, BHC returned +18.9% over the past year, against +12.0% for the S&P 500.
How many BHC shares are sold short?
7M shares were sold short at the latest FINRA report, 2.89% of the float, or 1.2 days of average trading volume.
Who are Bausch Health Companies's competitors?
Companies most similar to Bausch Health Companies by business, industry and size include VTRS, TEVA, GRFS, REGN, ZTS.
See a number that looks wrong?